Cas no 2834-79-9 (4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine)
4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine Chemical and Physical Properties
Names and Identifiers
-
- 2-Thiazolamine,4-[1,1'-biphenyl]-4-yl-
- 4-Biphenyl-4-yl-Thiazol-2-Ylamine
- 2-Amino-4-(4-biphenylyl)thiazole
- 4-(1,1'-Biphenyl-4-yl)-1,3-thiazol-2-amine
- 4-(4-phenylphenyl)-1,3-thiazol-2-amine
- 2-amino-4-(4-biphenyl)thiazole
- 4-([1,1'-biphenyl]-4-yl)thiazol-2-amine
- 4-(1,1'-biphenyl)-4-yl-2-thiazolamine
- 4-(biphenyl-4-yl)-1,3-thiazol-2-amine
- 4-(biphenyl-4-yl)thiazol-2-amine
- 4-Biphenyl-4-yl-thiazol-2-ylamin
- 4-Biphenyl-4-ylthiazol-2-ylamine
- F0777-1464
- Thiazole,2-amino-4-(4-biphenylyl)
- USAF EK-4373
- 4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine
- CHEMBL1426651
- CBDivE_012410
- HMS2653P23
- Z48847655
- 2-THIAZOLAMINE, 4-(1,1'-BIPHENYL)-4-YL-
- Q27256932
- Thiazole, 2-amino-4-(4-biphenylyl)-
- Cambridge id 5129029
- MFCD00047059
- F71727
- cid_76075
- LS-01088
- 39U8AA34OT
- [4-(4-phenylphenyl)thiazol-2-yl]amine
- 4-(1,1'-Biphenyl-4-yl)thiazole-2-amine
- CCG-327
- DTXSID20182579
- MLS001017970
- NCGC00246032-01
- 2-Thiazolamine, 4-[1,1'-biphenyl]-4-yl-
- 2-Amino-4-(p-diphenyl)thiazole
- 4-(4-PHENYLPHENYL)THIAZOL-2-AMINE
- EN300-02256
- 4-(4-phenylphenyl)-2-thiazolamine
- 4-{[1,1'-biphenyl]-4-yl}-1,3-thiazol-2-amine
- 2834-79-9
- SCHEMBL2907964
- 4-(4-phenylphenyl)-1, 3-thiazol-2-amine
- 4-(1,1'-biphenyl-4-yl)-2-amino-1,3-thiazole
- 4-27-00-05067 (Beilstein Handbook Reference)
- UNII-39U8AA34OT
- Oprea1_161040
- AB00074195-01
- BRN 0187642
- SMR000354210
- BDBM49948
- FT-0634510
- 4-[1,1'-Biphenyl]-4-yl-1,3-thiazol-2-amine #
- 4-biphenyl-4-yl-thiazol-2-ylamine, AldrichCPR
- HTAUVJPDFDVVHV-UHFFFAOYSA-N
- AKOS000115526
- A819419
- ALBB-000396
- STK502134
- DB-047381
-
- MDL: MFCD00047059
- Inchi: 1S/C15H12N2S/c16-15-17-14(10-18-15)13-8-6-12(7-9-13)11-4-2-1-3-5-11/h1-10H,(H2,16,17)
- InChI Key: HTAUVJPDFDVVHV-UHFFFAOYSA-N
- SMILES: S1C(N)=NC(=C1)C1C=CC(=CC=1)C1C=CC=CC=1
Computed Properties
- Exact Mass: 252.07200
- Monoisotopic Mass: 252.07211956g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 2
- Heavy Atom Count: 18
- Rotatable Bond Count: 2
- Complexity: 257
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 2
- XLogP3: 3.9
- Topological Polar Surface Area: 67.2?2
Experimental Properties
- Color/Form: Colorless powder.
- PSA: 67.15000
- LogP: 4.64050
- Solubility: Soluble in ethanol and ether, insoluble in water.
4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine Customs Data
- HS CODE:2934100090
- Customs Data:
China Customs Code:
2934100090Overview:
2934100090. Compounds that structurally contain a non fused thiazole ring(Whether hydrogenated or not). VAT:17.0%. Tax refund rate:9.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to
Summary:
2934100090 other compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0%
4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Fluorochem | 015332-1g |
4-Biphenyl-4-ylthiazol-2-ylamine |
2834-79-9 | 95+% | 1g |
£85.00 | 2022-03-01 | |
| Fluorochem | 015332-2.5g |
4-Biphenyl-4-ylthiazol-2-ylamine |
2834-79-9 | 95+% | 2.5g |
£181.00 | 2022-03-01 | |
| TRC | B413820-25mg |
4-([1,1'-Biphenyl]-4-yl)thiazol-2-amine |
2834-79-9 | 25mg |
$ 50.00 | 2022-06-07 | ||
| TRC | B413820-50mg |
4-([1,1'-Biphenyl]-4-yl)thiazol-2-amine |
2834-79-9 | 50mg |
$ 65.00 | 2022-06-07 | ||
| TRC | B413820-250mg |
4-([1,1'-Biphenyl]-4-yl)thiazol-2-amine |
2834-79-9 | 250mg |
$ 95.00 | 2022-06-07 | ||
| Alichem | A059006405-10g |
4-([1,1'-Biphenyl]-4-yl)thiazol-2-amine |
2834-79-9 | 95% | 10g |
$365.94 | 2023-09-02 | |
| Chemenu | CM112873-10g |
4-(1,1'-biphenyl-4-yl)-1,3-thiazol-2-amine |
2834-79-9 | 95% | 10g |
$416 | 2021-08-06 | |
| eNovation Chemicals LLC | Y1254821-1g |
4-BIPHENYL-4-YL-THIAZOL-2-YLAMINE |
2834-79-9 | 95% | 1g |
$180 | 2024-06-06 | |
| eNovation Chemicals LLC | Y1254821-5g |
4-BIPHENYL-4-YL-THIAZOL-2-YLAMINE |
2834-79-9 | 95% | 5g |
$470 | 2024-06-06 | |
| Chemenu | CM112873-1g |
4-(1,1'-biphenyl-4-yl)-1,3-thiazol-2-amine |
2834-79-9 | 95% | 1g |
$170 | 2024-07-28 |
4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine Suppliers
4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine Related Literature
-
Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
-
Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
-
Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
-
Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
-
Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
Additional information on 4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine
Research Brief on 4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine (CAS: 2834-79-9): Recent Advances and Applications
4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine (CAS: 2834-79-9) is a thiazole derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. Recent studies have explored its role as a key scaffold in the development of novel bioactive compounds, particularly in the areas of oncology, infectious diseases, and neurodegenerative disorders. This research brief synthesizes the latest findings on this compound, highlighting its chemical properties, biological activities, and emerging applications.
Recent investigations into the pharmacological profile of 4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine have revealed its promising activity as a kinase inhibitor. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent inhibitory effects against cyclin-dependent kinases (CDKs), which are critical targets in cancer therapy. The study utilized molecular docking and in vitro assays to elucidate the binding interactions and selectivity of these derivatives, paving the way for further optimization.
In addition to its anticancer potential, 4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine has shown efficacy against microbial pathogens. A 2022 report in Bioorganic & Medicinal Chemistry Letters highlighted its antibacterial properties, particularly against methicillin-resistant Staphylococcus aureus (MRSA). The compound's ability to disrupt bacterial cell wall synthesis was identified as a key mechanism of action, suggesting its utility in addressing antibiotic resistance.
The compound's structural versatility has also been exploited in the design of multifunctional agents for neurodegenerative diseases. A 2023 study in ACS Chemical Neuroscience reported that derivatives of 4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine exhibit dual activity as cholinesterase inhibitors and amyloid-beta aggregation inhibitors, making them potential candidates for Alzheimer's disease treatment. These findings underscore the compound's broad applicability in drug discovery.
From a synthetic chemistry perspective, recent advancements have focused on improving the yield and scalability of 4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine production. A 2023 paper in Organic Process Research & Development described a novel catalytic method that enhances the efficiency of the thiazole ring formation, reducing byproducts and environmental impact. This methodological innovation is expected to facilitate the compound's broader adoption in industrial and academic research settings.
In conclusion, 4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine (CAS: 2834-79-9) represents a versatile and pharmacologically relevant scaffold with diverse therapeutic applications. Ongoing research continues to uncover its potential, with recent studies emphasizing its role in kinase inhibition, antimicrobial activity, and neuroprotection. Future directions may include the development of more selective derivatives and the exploration of combination therapies. This compound remains a promising candidate for addressing unmet medical needs in multiple disease areas.
2834-79-9 (4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine) Related Products
- 56503-96-9(4-(naphthalen-1-yl)-1,3-thiazol-2-amine)
- 2103-91-5(4-(4-Methylphenyl)-1,3-thiazol-2-amine)
- 21331-43-1(4-(naphthalen-2-yl)-1,3-thiazol-2-amine)
- 85112-35-2(4-(4-ethylphenyl)-1,3-thiazol-2-amine)
- 2010-06-2(4-phenyl-1,3-thiazol-2-amine)
- 52253-69-7(2-Amino-4-phenylthiazole hydrobromide monohydrate)
- 34161-31-4(2-Thiazolamine,4-phenyl-, hydrobromide (1:1))
- 104296-00-6(4-(3,4-dimethylphenyl)-1,3-thiazol-2-amine)
- 24966-91-4(4-(4-methylphenyl)-1,3-thiazol-2-amine hydrobromide)
- 5330-67-6(4-(3-methylphenyl)-1,3-thiazol-2-amine)